FDA Flags Weak Root Cause Analysis in GMP Warning

A recent Warning Letter issued by the U.S. Food and Drug Administration to OraLabs Inc. (March 2026) highlights ongoing concerns around inadequate root cause analysis (RCA) and ineffective corrective and preventive actions (CAPA) during inspections.

The agency cited a violation of 21 CFR 211.192, noting the company failed to properly investigate unexplained discrepancies and microbiological deviations. In several instances, issues were dismissed without sufficient scientific evidence, raising concerns about product safety and compliance.

Key observations included unresolved or unclear causes, failure to evaluate all contributing factors such as manufacturing processes and environmental conditions, and underestimation of risks despite clear microbiological findings. Notably, some product lots were released to the market even when root causes remained uncertain.

The letter reinforces the FDA’s continued focus on ensuring that companies conduct thorough, science-based investigations and implement CAPAs that effectively prevent recurrence and safeguard product quality.

23-03-2026